Trelagliptin - CSPC ZhongQi Pharmaceutical Technology
Alternative Names: Trelagliptin succinate - CSPC ZhongQi Pharmaceutical TechnologyLatest Information Update: 23 Sep 2022
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class Amines; Antihyperglycaemics; Fluorobenzenes; Nitriles; Piperidines; Pyrimidinones; Small molecules; Succinates
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 23 Sep 2022 No development reported - Phase-III for Type 2 diabetes mellitus in China (PO) (CSPC ZhongQi Pharmaceutical Technology website, September 2022)
- 28 Dec 2020 CSPC ZhongQi Pharmaceutical Technology completes a phase III trial in Type 2 diabetes mellitus in China (PO) (NCT03940183)
- 08 Jul 2019 Phase-III clinical trials in Type 2 diabetes mellitus in China (PO) (NCT03940183)